Methods of identifying patients for treatment with HER-2/neu inhibitors based on detection of HER-2/neu and TOP2A gene copy number
US8105768B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Mar 8, 2006 |
| Grant date | Jan 31, 2012 |
| Priority date | — |
| Expiry date | Mar 8, 2026 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Q2600/106
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The present invention provides methods for identifying cancer patients susceptible to effective treatment with trastuzumab and other medications that function similarly to trastuzumab. The invention is based on the discovery that certain chromosomal abnormalities can be used to selectively identify cancer patients that are likely to be successfully treated with medication that inhibits the signaling capability of the HER-2 receptor protein or otherwise function similarly to trastuzumab. The invention is based on the use of nucleic acid technology where nucleic acid probes are allowed to hybridize to cell samples and the number of copies of particular genetic regions quantified. The present invention also provides kits and sets of probes for use in identifying cancer patients susceptible to effective treatment with trastuzumab and other medications that function similarly to trastuzumab.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.